| |
Article Title |
Author(s) |
Pages |
|
|
|
Masthead
|
|
IFC
|
|
| Secondary Analyses in Cardiovascular Clinical Trials - Statistical and Other Considerations |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Introduction
This special issue focuses on strengths and weaknesses of conducting secondary analyses in clinical trials and other studies. A discussion of the analytic approaches and limitations of such analyses a...
|
Barbara C. Tilley,
Barry R. Davis
|
329
|
|
|
|
Approaches to Data Analyses of Clinical Trials
Abstract: There are two types of data analyses of randomized clinical trials (RCTs). The primary analyses are pre-specified in the protocol and the findings form the basis for recommendations and clin...
|
Curt D. Furberg,
Lawrence M. Friedman
|
330-334
|
|
|
|
Secondary Analysis of Clinical Trials—A Cautionary Note
Abstract: There is concern in published reports and reviews that patients are being harmed or denied effective treatment by the use of questionable results from secondary analyses of data from clinica...
|
John R. Marler
|
335-337
|
|
|
|
Rudiments of Subgroup Analyses
Abstract: Subgroup analysis in a clinical trial is the evaluation of the effect of a randomly allocated intervention within only a fraction of the patients in the entire research cohort. This article ...
|
Lemuel A. Moyé
|
338-342
|
|
|
|
Surrogate End Points in Secondary Analyses of Cardiovascular Trials
Abstract: A surrogate end point is one that is used as a substitute for a clinical end point of more direct interest, usually for reasons of practicality, and that is expected to predict clinical bene...
|
Kevin A. Buhr
|
343-350
|
|
|
|
Economic Analysis of Secondary Trial Data
Abstract: Clinical trials may furnish data to conduct economic analyses. An economic analysis requires us to identify all opportunity costs associated with the intervention over the time horizon chose...
|
Kit N. Simpson,
Barbara C. Tilley
|
351-356
|
|
|
|
Comparison of the Global Statistical Test and Composite Outcome for Secondary Analyses of Multiple Coronary Heart Disease Outcomes
Abstract: Multiple outcomes (or multiple endpoints), such as mortality and recurrent myocardial infarction, are increasingly common in clinical trials and are often of interest in secondary analyses. ...
|
Sarah Baraniuk,
Roann Seay,
Arup K. Sinha,
Linda B. Piller
|
357-361
|
|
|
|
The High-Risk Myocardial Infarction Database Initiative
Abstract: Coronary artery disease and myocardial infarction represent a major cause of morbidity and mortality. Four randomized, controlled, double-blind clinical trials —VALIANT, EPHESUS, OPTIMAAL, a...
|
Kenneth Dickstein,
Judith Bebchuk,
Janet Wittes
|
362-366
|
|
|
|
Observational Epidemiology Within Randomized Clinical Trials: Getting a Lot for (Almost) Nothing
Abstract: Randomized clinical trials (RCTs) are considered the gold standard approach to establish relationships between exposures/treatments and outcomes. Analyses that examine the association betwee...
|
George Howard,
Virginia J. Howard
|
367-371
|
|
| Special Article |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Expanding the Benefits of Implantable Cardioverter-Defibrillator Therapy: “Is Less More”?
Abstract: Implantable cardioverter-defibrillator (ICD) therapy improves survival in patients with significant left ventricular systolic dysfunction. Although this lifesaving therapy has many benefits,...
|
Larry R. Jackson,
James P. Daubert,
Kevin L. Thomas
|
372-378
|
|
| Frontmatter |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Contents
|
|
A1
|
|
|
|
Recent Topics
|
|
A2
|
|
|
|
Editorial Board
|
|
A6
|
|
